According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00)

Page 1/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



PRASTERONUM

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Product name: Prasterone

Prasteronum Prasterone Prastérone Prasteron 53-43-0

N° CAS: 53-43-0 N° EC: 200-175-5

1.2 Relevant identified uses of the substance/mixture and uses advised against

Identified uses: Active Pharmaceutical Ingredient or Excipient.

1.3 Details of the supplier of the safety data sheet

Company: FAC SECUNDUM ARTEM NV

Oostmalsebaan 1c (unit 5)

2960 Sint-Lenaarts

Belgium

Telephone: (+32) (0)3 457 11 76

Email: info@magis-pharma.be

Web page: www.magis-pharma.be

1.4 Emergency telephone number

Public utility foundation: Belgisch Antigifcentrum Centre Antipoisons Belge

Telephone: (+32) (0)70 245 245 (Service 24/7)

Web page: www.antigifcentrum.be www.centreantipoisons.be

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance/mixture

Classification according to (EC) n° 1272/2008

Skin Irrit. 2 H315
Eye Irrit. 2 H319
STOT SE 3 H335
Repr. 1B H360
Lact. H362
Aquatic Acute 1 H400
Aquatic Chronic 1 H410

2.2 Label elements

Labelling according to (EC) n° 1272/2008

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PRASTERONUM

FORM-06-14-01 (V00)

Page 2/10

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01





Signal word(s): Attention; Danger

Hazard statements:

Hazard pictogram(s):

H315 Causes skin irritation.

H319 Causes serious eye irritation.
H335 May cause respiratory irritation.

H360 May damage fertility or the unborn child.
H362 May cause harm to breast-fed children.

H400 Very toxic to aquatic life.

H410 Very toxic to aquatic life with long-lasting effect.

Precautionary statements:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust/fumes/gas/mist/vapours/spray.
P261 Avoid breathing dust/fumes/gas/mist/vapours/spray.

P263 Avoid contact during pregnancy/while nursing.

P264 Wash hands thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.

P273 Avoid release to the environment.

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P281 Use personal protective equipment as required.
P302+P352 IF ON SKIN: Wash with soap and plenty of water.

P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if

present and easy to do - continue rinsing.

P308+P313 If exposed or concerned: Get medical advice/attention.

P312 Call a POISON CENTER/ doctor if you feel unwell.

P321 Specific treatment (see on this label).

P332+P313 If skin irritation occurs: Get medical advice/attention.
P337+P313 If eye irritation persists get medical advice/attention.

P362 Take off contaminated clothing.

P391 Collect spillage.

P403+P233 Store in a well-ventilated place. Keep container tightly closed.

P405 Store locked up.

P501 Dispose of contents/container in accordance with local/regional/national/international regulation.

Additional applicable label

elements:



According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PRASTERONUM

FORM-06-14-01 (V00)

Page 3/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



2.3 Other hazards

None.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Product name: Prasterone

IUPAC name: (35,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-

dodecahydrocyclopenta[a]phenanthren-17-one

Synonyms: DHEA

 3β -Hydroxy-5-androsten-17-one 5-Androsten-3 β -ol-17-one

Dehydroepiandrosterone Dehydroisoandrosterone

 N° CAS: 53-43-0 N° EC: 200-175-5 Molecular Formula: $C_{19}H_{28}O_2$

Content: 97.5 per cent to 102.0 per cent (anhydrous and solvent-free)

3.2 Mixtures

Not applicable.

SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures

After inhalation: If breathed in, move person into fresh air. If not breathing give artificial respiration

Consult a physician.

After skin contact: Remove contaminated clothing and shoes. Wash off with soap and plenty of water.

Consult a physician.

After eye contact: Rinse thoroughly with plenty of water for at least 15 minutes and consult a

physician.

After ingestion: Never give anything by mouth to an unconscious person. Rinse mouth with water.

Consult a physician.

4.2 Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11.

4.3 Indication of any immediate medical attention and special treatment needed

Not available.

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PRASTERONUM

FORM-06-14-01 (V00)

Page 4/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



Suitable extinguishing media:

Water spray, carbon dioxide, dry chemical powder or appropriate

foam.

Unsuitable extinguishing media: None.

5.2 Special hazards arising from the substance/mixture

Fire may cause evolution of: Carbon monoxide, carbon dioxide (CO₂), nitrogen oxides (NO_x).

5.3 Advice for firefighters

Surrounding fires: Not available.

Protection against fire: Wear self contained breathing apparatus for fire fighting if

necessary.

Hazardous combustion products: Not available.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Wear approved safety goggles, approved clothing and approved full face respirator P3.

For emergency responders

Wear approved safety goggles, approved clothing and approved full face respirator P3.

6.2 Environmental precautions

In case of accidental release or spill, keep away from drains, surface and ground water.

6.3 Methods and material for containment and cleaning up

Contain spillage, and then collect with non-combustible absorbent material, (e.g. sand, earth, diatomaceous earth, vermiculite) and place in container for disposal according to local/national regulations (see section 13). If emergency, enforce internal emergency plan.

6.4 Reference to other sections

For disposal, see section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Precautions for safe handling: Keep away from heat and flames. Avoid powder dispersion. Avoid

contact with incompatible substances. Avoid: direct contact with

skin and eyes; inhalation of vapours and fumes.

Personal protection: Wear appropriate PPE (See section 8).

Technical protective measures: Not available.

Handling: Occupational hygiene: Do not eat, drink or smoke in work areas.

Wash hands after use. Remove contaminated clothing and

protective equipment before entering eating areas.

7.2 Conditions for safe storage, including any incompatibilities

Storage: Not available.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PRASTERONUM

FORM-06-14-01 (V00)

Page 5/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



Conditions for safe storage, including any

incompatibilities:

Store at a temperature not exceeding 25 °C. Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Store locked up.

Storage – away from: Store protected from light and moisture.

7.3 Specific end use(s)

Active Pharmaceutical Ingredient or Excipient

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

OEL: $10 - 100 \mu g/m^3$

8.2 Exposure controls

Appropriate engineering control

Provide adequate engineering control measures in confined plants or with local exhaust ventilation systems, to avoid powder dispersion.

Individual protection measures

Eye/face protection: Approved safety goggles. Skin protection: Long sleeved clothing.

Hand protection: Rubber/latex/neoprene or other suitable chemical resistant gloves.

Respiratory protection: Approved full face respirator P3 or airline respirator.

Thermal hazards: Not determined.

Environmental exposure control

If necessary, adopt air emission treatment systems.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance: Fine, crystalline, white or approximately white powder.

Odour: Not available. Odour threshold: Not available. pH: Not available. Melting/freezing point: 146 °C - 151 °C Initial boiling point: Not available. Not available. Boiling range: Flash point: Not available. Not available. Evaporation rate: Flammability (solid/gas): Not available. Upper/lower flammability or Not available.

explosive limits:

Vapour pressure: 0.01Pa (25 °C)

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PRASTERONUM

FORM-06-14-01 (V00)

Page 6/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



Relative density: 1.159 g/cm³

Solubility: Freely soluble in ethanol (96 per cent) and in methylene chloride.

Solubility in water: Practically insoluble in water.

63.5 mg/L (25 °C)

Not available.

Partition coefficient Not available.

(n-octanol/water):

Vapour density:

Auto-ignition temperature: Not available.

Decomposition temperature: Not available.

Viscosity: Not available.

Explosive properties: Not available.

Oxidising properties: Not available.

9.2 Other information

Molecular Weight: 228,42 g/mol

Prasterone should not be considered as highly flammable.

SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity

Not available.

10.2 Chemical stability

The substance is stable in normal conditions of temperature and pressure and if stocked in closed containers in cold and ventilated area.

10.3 Possibility of hazardous reactions

Not available.

10.4 Conditions to avoid

Not available.

10.5 Incompatible materials

Strong oxidizing agents, acid.

10.6 Hazardous decomposition products

Hazardous decomposition products formed under fire conditions: carbon oxides.

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity: Oral LD₅₀ (rats): > 3 300mg/kg

Oral LD₅₀ (dogs): > 400 mg/kg

Oral LD₅₀ (male mice): > 4130 mg/kg Oral LD₅₀ (female mice): > 4 130 mg/kg

Skin corrosion/irritation: Conclusive but not sufficient for classification.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PRASTERONUM

FORM-06-14-01 (V00)

Page 7/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



Serious eye damage/irritation: Not available.

Germ cell mutagenicity: Conclusive but not sufficient for classification.

Carcinogenicity: Conclusive but not sufficient for classification.

Not available.

Reproductive toxicity: Repr. 1B, H360: May damage fertility or the unborn child

Effects via lactation: Effect on or via lactation H362: May cause harm to breast-fed

children.

Summary of evaluation of the

Respiratory/skin sensitisation:

CMR properties:

Not available.

STOT-single exposure: Not available.
STOT-repeated exposure: Not available.
Aspiration Hazard: Not available.

Other: Signs and Symptoms of Exposure: Electrolyte imbalance. To the best of our

knowledge, the chemical, physical, and toxicological properties have not been

thoroughly investigated. RTECS: BV8396000

11.2 Additional information on potential adverse human health effects and symptoms

Eye contact: Causes eye irritation.

Skin contact: May be harmful if absorbed through skin.

Causes skin irritation.

Inhalation: May be harmful if inhaled.

Causes respiratory tract irritation.

Ingestion: May be harmful if swallowed.

Aspiration: Not available.

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity

Hazardous to the aquatic environment (acute/short-term): Aquatic Acute 1 H400: Very toxic to aquatic life.

Hazardous to the aquatic environment (long-term): Aquatic Chronic 1 H410: Very toxic to aquatic life with long lasting effects.

12.2 Persistence and degradability

Prasterone is described as not readily biodegradable.

12.3 Bioaccumulative potential

The bioaccumulation factor of Prasterone was estimated to be 62.83 l/kg.

12.4 Mobility in soil

Not available.

12.5 Results of PBT and vPvB assessment

Not available.

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00)

Page 8/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



PRASTERONUM

12.6 Other adverse effects

No toxicity effect to microbes of activated sludge was observed.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product: Observe all federal, state, and local environmental regulations. Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging: Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION

14.1 UN Number

ADR/ RID(Land),IMDG(Sea), IATA/ICAO (Air):

3077

14.2 UN proper shipping name

ADR/ RID(Land),IMDG(Sea),

ADR/RID/ADN: PRASTERON

IATA/ICAO (Air):

IMDG: PRASTERON
IATA/ICAO: PRASTERON

14.3 Transport hazard class(es)

ADR/RID(Land),IMDG(Sea),

IATA/ICAO (Air):

9

Ш

14.4 Packing group

ADR/RID(Land),IMDG(Sea),

٦),

IATA/ICAO (Air):

14.5 Environmental hazards

ADR/ RID(Land), IMDG(Sea),

ADR/RID/ADN: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID

IATA/ICAO (Air): IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID

IATA/ICAO: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID

14.6 Special precautions for user

Not available.

14.7 Transport in bulk according to annex II of Marpol and the IBC Code

Not available.

14.8 Additional transport information

Not available.

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance/mixture

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

PRASTERONUM

FORM-06-14-01 (V00)

Page 9/10

ΕN

Publication: 03/05/2022

Revision: 24/08/2023

Version: 01



Hazard symbol:

X

Irritant Harmful

Risk phrases: R36/37/38 Irritating to eyes, respiratory system and skin.

R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in

the aquatic environment. R60 May impair fertility.

R61 May cause harm to the unborn child. R64 May cause harm to breast-fed babies.

Safety phrases: S1 Keep locked up.

S7/9 Keep container tightly closed and in a well-ventilated place.

S20/21 When using do no teat, drink or smoke.

S23 Do not breathe dust/fumes/gas/mist/vapours/spray.

S26 In case of contact with eyes, rinse immediately with plenty of water and seek

medical advice.

S27 Take off immediately all contaminated clothing.

S28 After contact with skin, wash immediately with soap and plenty of water. S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.

S51 Use only in well-ventilated areas.

S53 Avoid exposure- obtain special precautions before use.

S61 Avoid release to the environment. Refer to special instructions/Safety data

sheets.

15.2 Chemical safety assessment

Not available.

SECTION 16: OTHER INFORMATION

16.1 Changes since the previous version

Not applicable.

16.2 Abbreviations and acronyms used

ADR: European Agreement concerning the International Carriage of Dangerous Goods by

Road

CAS: Chemical Abstracts Service (division of the American Chemical Society)

EC (number): European Community (number)

IATA: International Air Transport Association

ICAO: International Civil Aviation Organization

IMDG: International Maritime Code for Dangerous Goods

IUPAC: International Union of Pure and Applied Chemistry

PBT: Persistent, Bioaccumulative and Toxic substance

According to (EC) No 1907/2006 (REACH) and 1272/2008 (CLP)

FORM-06-14-01 (V00)

Page 10/10

ΕN

Publication: 03/05/2022 Revision: 24/08/2023

Version: 01



PRASTERONUM

RID: Regulations Concerning the International Transport of Dangerous Goods by Rail

STOT: Specific Target Organ Toxicity

UN (number): United Nations (number)

vPvB: very Persistent and very Bioaccumalative

16.3 Key literature references/sources for data

European Chemicals Agency.

https://www.echa.europa.eu/web/guest/information-on-chemicals/cl-inventory-database/

16.4 Method of classification in case of mixture

Not applicable.

16.5 Relevant Hazard statements and/or precautionary statements

For information on hazard and/or precautionary statements refer to section 2 up to and including section 15.

16.6 Training advisement

Not available

16.7 Notice for user(s)

The information provided in this MSDS has been established in accordance with Commission Regulation (EU) 2015/830 of 28 May 2015, amending Regulation (EC) No 1907/2006 of the European Parliament and of the Council, on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing the European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94, as well as Council Directive 76/769/EEC and Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC of the Commission.

This MSDS is intended to provide a brief summary of our knowledge and guidance regarding the use of this material. The information has been compiled from sources considered to be dependable and is accurate to the best of the FSA NV's knowledge. However, the information is provided without any representation or warranty, expressed or implied regarding its accuracy or correctness. FSA NV cannot assume responsibility for adverse events which may occur in the use and/or misuse of this product and expressly disclaims liability for loss, damage and/or expense arising out of or in any way connected with the handling, storage, use and/or disposal of this product.

16.8 Department issuing MSDS

Quality Department

FAC SECUNDUM ARTEM NV

info@magis-pharma.be